Early diagnosis of capivasertib-associated severe hyperglycemia with diabetic ketosis diagnosed in routine clinical practice: a case report with review of literature
{{output}}
Capivasertib, an oral pan-AKT inhibitor, is a therapeutic option for hormone receptor-positive advanced breast cancer. While hyperglycemia is a recognized adverse effect of AKT inhibition, its diagnosis is often delayed in routine clinical practice. We report ... ...
